Home - Blank Rome LLP

Register to receive insights and analyses on breaking news and trends across varying industries.
<a class="link-primary mt-4" href="/subscribe">Subscribe</a>

Philadelphia, PA

New York, NY

Wilmington, DE

Cincinnati, OH

Princeton, NJ

Los Angeles, CA

Houston, TX

Tampa, FL

Shanghai

South Florida

Pittsburgh, PA

Washington, D.C.

Chicago, IL

Orange County, CA

Dallas, TX

Boston, MA

Blank Rome partner <a href="/people/rachael-g-pontikes/" id="18670">Rachael G. Pontikes</a> will serve as a panelist at American Conference Institute’s (“ACI”) <a href="https://www.americanconference.com/glp-1-law-policy/">Inaugural Summit on GLP‑1 Law &amp; Policy</a>, being held virtually on Thursday, July 24, 2025, from 8:15 a.m. to 5:15 p.m.

core/paragraph

core/heading

The GLP‑1 drug market, now exceeding $100 billion, is rapidly expanding. While the market boom in GLP‑1 drugs presents enormous financial opportunities for life sciences companies, it also carries substantial legal, regulatory, and reimbursement risks. Political shifts may potentially impacting Medicare/Medicaid, new leadership at the Food and Drug Administration is increasing compliance pressure, and new entrants to the market are compounding existing litigation and market share exclusivity risks. Industry leaders will discuss the opportunities and challenges of this booming industry.

Rachael’s session, “Protecting Exclusivity: Drug Classification, Compounding Risks, and Market Access Challenges,” will take place from 10:45 to 11:45 a.m. EDT

As the GLP‑1 market shifts, understanding the impact of drug classification on market access and pricing and the long-term commercial implications of regulatory decisions is critical. This session will focus on developing strategies for maintaining exclusivity and favorable categorization.

Understanding how large molecule v. small molecule classification impacts regulatory approval and market exclusivity

core/list-item

Responding to increased FDA scrutiny of compounding pharmacies and telehealth providers

core/list

Assessing the evolving exclusivity strategies to counter patent challenges

Edgar J. Asebey, Managing Partner, Asebey Life Science Law

Julie Dohm, Partner, Covington &amp; Burling LLP

Guilherme Ferrari Faviero, Esq., MS, MPH, Director, AHF Global Public Health Institute at the University of Miami

Rachael G. Pontikes, Partner, Blank Rome LLP

The Future of GLP-1s: Market Trends, Business Models &amp; Legal Hurdles

Defending Market Position: IP, Regulatory &amp; Enforcement Challenges in the GLP‑1 Market

Market Access, Cost Containment &amp; Compliance Challenges

Expanding the Therapeutic Horizons of GLP‑1 Drugs: The Future of Incretin-Based Therapies

Strategic Deals and Investment Moves Influencing the Marketplace

The Next 5 Years: What to Expect for the Future of GLP‑1s

For more information and to register, please visit the&nbsp;<a href="https://www.americanconference.com/glp-1-law-policy/">event webpage</a>.

Protecting Exclusivity: Drug Classification, Compounding Risks, and Market Access Challenges

Offices

Stay Connected

Slide Menu

Slide Search

Protecting Exclusivity: Drug Classification, Compounding Risks, and Market Access Challenges

Offices

Stay Connected